Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Strategic Expansion into AI-Powered Healthcare Solutions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mustang Bio Inc MBIO

Healthcare Biotechnology
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for cancers and rare genetic diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR-T) therapies across multiple cancers, as well as lentiviral gene... see more

Recent & Breaking News (NDAQ:MBIO)

Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

GlobeNewswire November 12, 2021

Mustang Bio Announces Exclusive Worldwide License Agreement with Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy with Curative Potential for RAG1 Severe Combined Immunodeficiency

GlobeNewswire November 10, 2021

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting

GlobeNewswire November 4, 2021

Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy for Treatment of B-cell non-Hodgkin Lymphomas

GlobeNewswire November 1, 2021

Mustang Bio to Participate in Chardan's Virtual 5th Annual Genetic Medicines Conference

GlobeNewswire September 30, 2021

Mustang Bio Announces MB-101 (IL13Rα2‐targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences

GlobeNewswire September 28, 2021

Mustang Bio to Participate in Three September 2021 Investor Conferences

GlobeNewswire September 9, 2021

Mustang Bio Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights

GlobeNewswire August 16, 2021

Mustang Bio Collaborates with Mayo Clinic on Novel CAR T Technology

GlobeNewswire August 12, 2021

Mustang Bio Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants

GlobeNewswire August 2, 2021

Mustang Bio Awarded Massachusetts Life Sciences Center Tax Incentive

GlobeNewswire June 17, 2021

Mustang Bio to Present at the Raymond James Human Health Innovation Conference

GlobeNewswire June 16, 2021

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

GlobeNewswire June 11, 2021

Mustang Bio to Host Key Opinion Leader Webinar on MB-106 CD20-Targeted CAR T for the Treatment of High-Risk B-Cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

GlobeNewswire June 7, 2021

Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 (IL13R?2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors

GlobeNewswire May 18, 2021

Mustang Bio Reports First Quarter 2021 Financial Results and Recent Corporate Highlights

GlobeNewswire May 14, 2021

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress

GlobeNewswire May 12, 2021

Mustang Bio Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy

GlobeNewswire May 10, 2021

Mustang Bio to Participate in Chardan's 5th Annual Genetic Medicines Manufacturing Summit

GlobeNewswire April 21, 2021

Mustang Bio Reports Full-Year 2020 Financial Results and Recent Corporate Highlights

GlobeNewswire March 24, 2021